Estimating Treatment Effect of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer Using Bayesian Networks-Reference-Cited by-同舟云学术

Estimating Treatment Effect of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer Using Bayesian Networks

Published:2023-09 Issue:7 Volume: Page:
ISSN:2473-4276
Container-title:JCO Clinical Cancer Informatics
language:en
Short-container-title:JCO Clinical Cancer Informatics

Author:

Sieswerda Melle¹²^ORCID,van Rossum Ruby¹,Bermejo Inigo²,Geleijnse Gijs¹^ORCID,Aben Katja¹³^ORCID,van Erning Felice¹⁴^ORCID,de Hingh Ignace¹⁴,Lemmens Valery²,Dekker André²^ORCID,Verbeek Xander¹

Affiliation:

1. Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands

2. Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands

3. Department for Health Evidence, Radboud University Medical Centre, Nijmegen, the Netherlands

4. Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands

Abstract

Advanced statistical analysis (with BNs) suggests that oxaliplatin should be avoided in elderly patients.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

General Medicine

Link

https://ascopubs.org/doi/pdfdirect/10.1200/CCI.23.00080

Reference29 articles.

1. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy

2. Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial

3. Matching Using Estimated Propensity Scores: Relating Theory to Practice

4. Estimating Causal Effects from Large Data Sets Using Propensity Scores

5. Propensity score and doubly robust methods for estimating the effect of treatment on censored cost